http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Hwang, Jeong Won,Oh, Jung Han,Yoo, Hwa-Seung,Lee, Yeon-Weol,Cho, Chong-Kwan,Kwon, Ki-Rok,Yoon, Jung-Ho,Park, Junsoo,Her, Song,Lee, Zee-Won,Jang, Ik-Soon,Choi, Jong-Soon Institute for Advanced Research in Asian Science a 2012 The American journal of Chinese medicine Vol.40 No.1
<P>Administration of mountain ginseng (MG) extract can restore advanced cancer to a normal state. To elucidate the mechanism by which MG extract prevents the progression of lung cancer, the processes of proliferation and death of lung cancer cells (A549) were examined after treatment with MG extract. Butanol-extracted MG (BX-MG) showed a high inhibitory effect (IC(50) = 2 mg/ml) by attenuating proliferation and inducing apoptosis in lung cancer cells. By HPLC-UV analysis of BX-MG, ginsenosides, Rb1 was identified as the most abundant ginsenoside, followed by Rg1, Re, Rc and Rb2. BX-MG induced caspase-3 dependent apoptosis by inhibiting NF-관B. In addition, BX-MG activated p53 and p21, resulting in the attenuated proliferation of A549 cells. Reduced activity of the NF-관B promoter and increased activity of the p53 promoter indicate that BX-MG regulates apoptosis at the level of transcription in lung cancer cells. Furthermore, BX-MG blocked the nuclear translocation of RelA and the associated reduction in surviving. These results suggest that BX-MG inhibits lung cancer cell growth by activating tumor suppressors and inhibiting nuclear translocation of NF-관B.</P>
Yoo, Ki-Yeon,Yoo, Dae Young,Hwang, In Koo,Park, Joon Ha,Lee, Choong Hyun,Choi, Jung Hoon,Kwon, Seung-Hae,Her, Song,Lee, Yun Lyul,Won, Moo-Ho Kluwer Academic/Plenum Publishers 2011 Neurochem Res Vol.36 No.12
<P>Innate immune system is very important to modulate the host defense against a large variety of pathogens. Toll-like receptors (TLRs) play a key role in controlling innate immune response. Among TLRs, TLR4 is a specific receptor for lipopolysaccharide and associated with the release of pro-inflammatory cytokines. In the present study, we investigated ischemia-related changes of TLR4 immunoreactivity and its protein level, and nuclear factor κB (NF-κB) p65 immunoreactivity regarding inflammatory responses in the hippocampal CA1 region after 5 min of transient cerebral ischemia to identify the correlation between transient ischemia and inflammation. In the sham-operated group, TLR4 immunoreactivity was easily detected in pyramidal neurons of the hippocampal CA1 region (CA1). TLR4 immunoreactivity in pyramidal neurons was distinctively decreased after ischemia/reperfusion (I/R); instead, based on double immunofluorescence study, TLR4 immunoreactivity was expressed in non-pyramidal neurons and astrocytes from 2 days postischemia. In addition, TLR4 protein level was lowest at 1 day postischemia and highest 4 days after I/R. On the other hand, NF-κB p65 immunoreactivity was not detected in the CA1 of the sham-operated group, and NF-κB p65 immunoreactivity was not observed until 1 day after I/R. However, NF-κB p65 immunoreactivity began to be expressed in astrocytes at 2 days postischemia, and the immunoreactivity was strong 4 days postischemia. Our results indicate that TLR4 and NF-κB p65 immunoreactivity are changed in CA1 pyramidal neurons and newly expressed in astrocytes, not in microglia, in the CA1 region after transient cerebral ischemia.</P>
Kim, Bo Hyun,Ko, Young-Guk,Her, Ae-Young,Kim, Jung-Sun,Hwang, Ki-Chul,Shin, Dong-Ho,Kim, Byeong-Keuk,Choi, Donghoon,Ha, Jong-Won,Hong, Myeong-Ki,Jang, Yangsoo The Korean Society of Cardiology 2012 Korean Circulation Journal Vol.42 No.7
<P><B>Background and Objectives</B></P><P>Patients with acute myocardial infarction show varying degrees of collateral development. However, the relationships between angiogenic factors and degree of collaterals are not well known.</P><P><B>Subjects and Methods</B></P><P>Fifty-nine patients (mean age, 59±10 years) with ST-segment elevation myocardial infarction (STEMI) underwent primary percutaneous coronary intervention (PCI). Patients were divided into one of 2 groups: group I (Rentrop collateral grade 0/1, n=34) or group II (grade 2/3, n=25). Plasma levels of vascular endothelial growth factor (VEGF), soluble VEGF receptor (sFlt-1), angiopoietin (Ang)-2, and soluble Tie-2 at baseline, 24 and 48 hours after PCI were measured.</P><P><B>Results</B></P><P>There were fewer diabetic patients and higher incidence of previous angina and multi-vessel disease in group II. Group II had a lower left ventricular ejection fraction and a trend toward longer pain-to-balloon time. Plasma levels of Ang-2, sFlt-1 were elevated prior to primary PCI and decreased after PCI, whereas plasma level of VEGF was relatively low initially, however rose after PCI. sTie-2 levels showed no significant interval change in group I, but decreased over time in group II. VEGF, sFlt-1, and Tie-2 levels did not differ between the groups at each time point. However, plasma levels of Ang-2 were higher in group I than in group II at baseline and at 48 hours.</P><P><B>Conclusion</B></P><P>Presence of collaterals in STEMI patients undergoing primary PCI was associated with lesser rise in Ang-2 plasma level. VEGF showed a delayed response to acute ischemia compared to Ang-2. Clinical implications of our findings need to be investigated in further studies.</P>
Park, Hoon Suk,Kim, Chan Joon,Yi, Jeong-Eun,Hwang, Byung-Hee,Kim, Tae-Hoon,Koh, Yoon Seok,Park, Hun-Jun,Her, Sung-Ho,Jang, Sung Won,Park, Chul-Soo,Lee, Jong Min,Kim, Hee Yeol,Jeon, Doo Soo,Kim, Pum-Jo S. Karger AG 2015 Cardiorenal medicine Vol.5 No.1
<P>Abstract</P><P><B><I>Background:</I></B> Considering that contrast medium is excreted through the whole kidney in a similar manner to drug excretion, the use of raw estimated glomerular filtration rate (eGFR) rather than body surface area (BSA)-normalized eGFR is thought to be more appropriate for evaluating the risk of contrast-induced acute kidney injury (CI-AKI). <B><I>Methods:</I></B> This study included 2,189 myocardial infarction patients treated with percutaneous coronary intervention. Logistic regression analysis was performed to identify the independent risk factors. We used receiver-operating characteristic (ROC) curves to compare the ratios of contrast volume (CV) to eGFR with and without BSA normalization in predicting CI-AKI. <B><I>Results:</I></B> The area under the curve (AUC) of the ROC curve for the model including all the significant variables such as diabetes mellitus, left ventricular ejection fraction, preprocedural glucose, and the CV/raw modification of diet in renal disease (MDRD) eGFR ratio was 0.768 [95% confidence interval (CI), 0.720-0.816; p < 0.001]. When the CV/raw MDRD eGFR ratio was used as a single risk value, the AUC of the ROC curve was 0.650 (95% CI, 0.590-0.711; p < 0.001). When the CV/MDRD eGFR ratio with BSA normalization ratio was used, the AUC of the ROC curve further decreased to 0.635 (95% CI, 0.574-0.696; p < 0.001). The difference between the two AUCs was significant (p = 0.002). <B><I>Conclusions:</I></B> Raw eGFR is a better predictor for CI-AKI than BSA-normalized eGFR.</P><P>© 2015 S. Karger AG, Basel</P>
Jong Man Kim,Sung Yoo Cho,Jinsoo Rhu,Miyoung Jung,Jung Hyun Her,Okjae Lim,Gyu-Seong Choi,Eui-Cheol Shin,Yu-Kyeong Hwang,Jae-Won Joh 한국간담췌외과학회 2021 Annals of hepato-biliary-pancreatic surgery Vol.25 No.2
Backgrounds/Aims: Fewer reports have been published regarding hepatectomy patients with solitary hepatocellular carcinoma (HCC) who received immunotherapeutic agents as adjuvant therapy. We evaluated the safety and efficacy of ex vivo-expanded allogenic natural killer (NK) cells in those patients with modified International Union Against Cancer (UICC) stage T3. Methods: From August 2014 to October 2015, five patients who underwent hepatic resection received ex vivo-expanded allogenic NK cells. Patients received five rounds of NK cells (2-3×10<SUP>7</SUP> cells/kg) at postoperative 4, 6, 8, 12, and 16 weeks. This study is registered with ClinicalTrials.gov, number NCT02008929. Results: The median age of the five patients (three men and two women) was 44.8 years (range, 36-54 years). All had hepatitis B virus-related HCC, and the median tumor size was 2.2 cm (range, 2.1-8.2 cm). None of the patients had any adverse events. HCC recurrence developed in two patients at one year after hepatic resection, but four patients were alive at 3 years. The two recurrence-free patients showed a higher ratio of CD8+ T lymphocyte populations before and after administration of ex vivo-expanded allogenic NK cells compared with the three patients who experienced recurrence. Conclusions: Immunotherapy using ex vivo-expanded allogenic NK cells in hepatectomy patients can be used safely. Further studies should be investigated for efficacy.
Impact of initial blood flow on outcomes of vascular access in hemodialysis patients
( Soo Jeong Choi ),( Moo Yong Park ),( Jin Kuk Kim ),( Seung Duk Hwang ),( Kyun Her ),( Yongsoon Won ) 대한신장학회 2012 Kidney Research and Clinical Practice Vol.31 No.3
Background: Direct access flow measurements are considered the most useful surveillance method for significant stenosis, and ultrasound dilution has become the most popular and validated technique. The goal of this study was to evaluate access flow(Qa)atthetimeoffirstcannulationanditsrelationshiptothesurvival of vascular access in Korean hemodialysis patients. Methods: We conducted a prospective observational study from May 2004 to June 2011. We enrolled 60 patients (36men) who underwent the first access operation between January 2004 and December 2005 and were followed-up for surveillance. Results: Maturation failure occurred in nine patients (15%). Mean time to first use was 1.87±1.2 months after surgery. The patients were followed-up for a mean of 50.5±25.9 months. There were 25 deaths and six kidney transplants in patients with a functioning access. The total percutaneous transluminal angioplasty incidence was 50 in 27 patients(0.14/access-year). The initial Qa was 757.5±476.4 mL/minute. First cannulation time was not significantly correlated with initial Qa(r=0.234, P=0.075). A total of 22 of the 60 patients(36.7%) had an initial Qa<500mL/minute. Maturation failure, initial Qa<500mL/minute, and the use of antiplatelet agents were risk factors for poor primary patency. Diabetic status and use of a graft were risk factors for low cumulative patency. Conclusion: An initial Qa<500mL/minute is a risk factor for poor primary patency, while an initial Qa<500mL/minute is not a risk factor for low cumulative patency or mortality.
Hyun Lee, Choong,Yan, Bingchun,Yoo, Ki‐,Yeon,Choi, Jung Hoon,Kwon, Seung‐,Hae,Her, Song,Sohn, Youdong,Hwang, In Koo,Cho, Jun Hwi,Kim, Young‐,Myeong,Won, Moo‐,Ho Wiley Subscription Services, Inc., A Wiley Company 2011 Journal of neuroscience research Vol.89 No.7
<P><B>Abstract</B></P><P>Glucagon‐like peptide‐1 receptor (GLP‐1R) protects against neuronal damages in the brain. In the present study, ischemia‐induced changes in GLP‐1R immunoreactivity in the gerbil hippocampal CA1 region were evaluated after transient cerebral ischemia; in addition, the neuroprotective effect of the GLP‐1R agonist exendin‐4 (EX‐4) against ischemic damage was studied. GLP‐1R immunoreactivity and its protein levels in the ischemic CA1 region were highest at 1 day after ischemia/reperfusion (I/R). At 4 days after I/R, GLP‐1R immunoreactivity was hardly detected in CA1 pyramidal neurons, and its protein level was lowest. GLP‐1R protein level was increased again at 10 days after I/R, and GLP‐1R immunoreactivity was found in astrocytes and GABAergic interneurons. In addition, EX‐4 treatment attenuated ischemia‐induced hyperactivity, neuronal damage, and microglial activation in the ischemic CA1 region in a dose‐dependent manner. EX‐4 treatment also induced the elevation of GLP‐1R immunoreactivity and protein levels in the ischemic CA1 region. These results indicate that GLP‐1R is altered in the ischemic region after an ischemic insult and that EX‐4 protects against ischemia‐induced neuronal death possibly by increasing GLP‐1R expression and attenuating microglial activation against transient cerebral ischemic damage. © 2011 Wiley‐Liss, Inc.</P>